Royalty Report: Diagnostic, Disease, Drugs – Collection: 319183

$100.00

Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 4

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 4

Primary Industries

  • Diagnostic
  • Disease
  • Drugs
  • Biotechnology
  • Medical
  • Osteoarthritis
  • cardiac
  • Cancer

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 319183

License Grant
Licensor grants a non-exclusive license, without the right to grant sublicenses, under the Licensed Patent Rights and Licensed Technology to make, distribute, use and sell Licensed Products within the Field and in the Territory.
License Property
Licensor is the owner of or otherwise controls certain patents and technology related to its proprietary DNA-based PST® Genetic Risk Assessment Test that may be used for the identification of persons at risk for developing periodontis.

Licensed Product means any product that uses, incorporates, is comprised of, or contains a PST® Genetic Risk Assessment Test.

Licensed Technology means any Technology Controlled by Licensor at any time during the Term that is related to the PST® Genetic Risk Assessment Test and is necessary or useful for Oral DNA to exercise the license granted.

PST® Genetic Risk Assessment Test means Licensors proprietary genetic test covered by one or more Licensed Patent Rights that detects variations in certain Interleukin-I genes in order to identify an individuals predisposition for over-expression of inflammation and risk for periodontal disease.

Field of Use
The PST® Genetic Test provides a means of assessing an individual's genetic risk for periodontal disease, the most common cause of tooth loss.  PST(R) Genetic Test is the first and only genetic test that analyzes interleukin 1 (IL1) genes for variations that identify an individual's predisposition for over-expression of inflammation and risk for more severe periodontal disease. The PST(R) Genetic Test was developed following numerous clinical studies, and more than 40 peer-reviewed articles have been published on the test.

The Field means all activities associated with the Diagnosis of periodontal disease.

Licensee desires to obtain patents and technology to make, distribute, use and sell PST® Genetic Risk Assessment Tests for use in the Field.

IPSCIO Record ID: 5423

License Grant
An arrangement whereby the Party acquired the right to develop and commercialize Sheffield’s past and future discoveries.  PST technology–a genetic test that predicts the risk of periodontal disease and other tests which predict genetic susceptibility.
Field of Use
The rights granted apply to the healthcare industry.

IPSCIO Record ID: 239023

License Grant
Licensor grants an exclusive license, with the right to grant sublicenses, to practice in the Licensed Field under the Licensor Patent Rights, the Licensor Technology and Licensors interest in the Program Patent Rights and Program Inventions and to make, have made, use, sell, offer for sale and import Nutrigenomics Consumables and Dermagenomics Consumables in the Licensed Territory and in the Licensed Field, and to sell Nutrigenomics Tests and Dermagenomics Tests in the Licensed Territory and in the Licensed Field.
License Property
Licensor has technology relating to analyzing the effect of variations in genes related to inflammation, including but not limited to the effect of such variations on the risk for osteoporosis and cardiovascular disease, and determining through genetic profiling, individuals who may benefit from specific interventions to promote health, and owns the patents and patent applications which disclose and claim certain aspects of the technology.

Patents include, but are not limited to, Methods and Compositions for Pharma. Ana!ysis of Anti-Inflammatory Drugs in the Treatment of Rheumatoid Arthritis and Other lnflammatory Diseases, and, Diagnostlcs and Therapeutics for an Obstructive Airway Disease, and, Detecting Genetic Predisposition to Sight Threatening Diabetic Retinopathy.

Field of Use
Licensed Field means the Dermagenomics and Nutrigenomics Fields for products or services and Biomarker Tests for use with Dermagenomics and Nutrigenomics Consumables.

Dermagenomics Field means products, compositions, apparatuses, processes, and business services that, would be legally available without a prescription, and relate to skin care, including but not limited to, Dermagenomics Consumables.

Nutrigenomics Field means products, compositions, apparatuses, processes, and business services that,  would be legally available without a prescription, and relate to nutritional supplements or nutraceutical compounds, including but not limited to, Nutrigenomics Consumables.

IPSCIO Record ID: 2305

License Grant
Licensor is providing the Company with an exclusive worldwide license to Licensor’s existing and future human genome technologies that are useful for the purposes of development and commercialization of certain of the Company's services, including (i) testing, detection and/or analysis of cancer-predisposing genes; (ii) genetic assessment of risk of an individual to develop cancer; and (iii) testing and analysis for the purposes of cancer management.
License Property
The proprietary technologies include functional gene assay and microsatellite instability technology.  In addition, the Company currently uses conventional gene sequencing to detect gene mutations.  The Company intends to utilize protein truncation methods, Oncor’s proprietary Tri-Amp DNA amplification technology, various gel electrophoresis screening methods and automation to detect genetic mutations.
Field of Use
The Licensee was formed to develop genetic testing and information services for the early detection and management of cancer.  Also engaged in research and development programs and organizational efforts.  The rights granted apply to the healthcare industry.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.